Cambridge, United States
uMed's key offering is the ACCESS Research Platform, which is integrated across a global network of healthcare institutions. This platform enables researchers to efficiently access and engage with patients, facilitating the collection of electronic health records, clinical outcomes, patient-reported data, and biosamples from decentralized sources.
The latest funding round for uMed was a substantial £9.80M Series A investment, which took place on 04 July 2023. The investment was backed by 11.2 Capital, Playfair Capital, Albion VC, and Delin Ventures. This strategic financial support will likely enhance uMed's capacity to develop and implement their research acceleration and patient outcome improvement solutions on a wider scale.
DatStat, an R1 company